SCHEMBL6347114

SCHEMBL6347114

C[Si](C)(C)c1nc2ccccc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
MASP2 O00187 1/20 0.57
MEN1 O00255 1/20 0.57
NUDT1 P36639 1/20 0.57
KMT2A Q03164 1/20 0.57
AOC3 Q16853 1/20 0.57
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
NPSR1 Q6W5P4 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
KDM4E B2RXH2 2/20 0.56
PKM P14618 2/20 0.56
ABCB11 O95342 1/20 0.56
TP53 P04637 1/20 0.56
HSD17B10 Q99714 1/20 0.56
DDAH1 O94760 1/20 0.52
GAA P10253 1/20 0.48
POLB P06746 3/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13942760 0.78 ALDH1A1 (0.56) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL28573586 0.74 DDAH1 (0.51) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL30587443 0.73 ALDH1A1 (1.00) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL29391888 0.73 RAB9A (0.66) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL111276 0.73 RAB9A (0.66) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL9098 0.73 ALDH1A1 (1.00) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL5924625 0.73 ALDH1A1 (0.60) ALDH1A1MASP2MEN1NUDT1KMT2A
SCHEMBL172216 0.72 NPC1 (1.00) ALDH1A1NPC1RAB9ANPSR1SMN1; SMN2
SCHEMBL30634854 0.72 NPC1 (1.00) ALDH1A1NPC1RAB9ANPSR1SMN1; SMN2
SCHEMBL30561047 0.72 NPC1 (1.00) ALDH1A1NPC1RAB9ANPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951948-B2 Method for synthesis of substituted azole libraries ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-10-04 US disclosed
US-6683191-B2 PREPARING A AZOLE COMPOUND ON A SOLID SUPPORT RESIN, CLEAVING THE COMPOUND FROM THE SOLID SUPPORT RESIN BY NUCLEOPHILIC SUBSTITUTION TO FURTHER SUBSTITUTING BY ALKYLATION REACTION ORTHO-MCNEIL PHARMACEUTICALS, INC. 2004-01-27 US disclosed
US-20020077483-A1 Method for synthesis of substituted azole libraries ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-06-20 US disclosed
US-20020042520-A1 Method for synthesis of substituted azole libraries ORTHO-MCNEIL PHARMACEUTICALS, INC. 2002-04-11 US disclosed
WO-2001094317-A2 METHOD FOR SYNTHESIS OF SUBSTITUTED AZOLE LIBRARIES ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-12-13 WO disclosed
WO-2001094318-A2 METHOD FOR SYNTHESIS OF SUBSTITUTED AZOLE LIBRARIES ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-12-13 WO disclosed
EP-0295401-A2 Process for polymerizing polar compounds WACKER-CHEMIE GMBH (DE) 1988-12-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020077483-A1 Method for synthesis of substituted azole libraries CYP51A1, LSS, CYP2F1 ALDH1A1 711/4885MASP2 2750/4885MEN1 214/4885
US-20020042520-A1 Method for synthesis of substituted azole libraries CYP51A1, LSS, CYP2F1 ALDH1A1 711/4885MASP2 2750/4885MEN1 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.